Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer (Protocol SPI-612)
Conditions
Interventions
Apaziquone
Placebo
+1 more
Locations
77
United States
Advanced Urology Medical Center Clinical Trials
Anaheim, California, United States
Hal J. Bashein, D.O.
West Palm Beach, Florida, United States
Urology Enterprises
Marietta, Georgia, United States
North Fulton Urology
Roswell, Georgia, United States
Hines VA Hospital
Hines, Illinois, United States
The Urology Center
Slidell, Louisiana, United States
Start Date
August 1, 2007
Primary Completion Date
January 1, 2012
Completion Date
January 1, 2012
Last Updated
November 13, 2017
NCT04235764
NCT03375307
NCT07061964
NCT00026884
NCT04585750
NCT07050771
Lead Sponsor
Spectrum Pharmaceuticals, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions